De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
ProQR Therapeutics Beheer
Beheer criteriumcontroles 3/4
De CEO ProQR Therapeutics' is Daniel de Boer, benoemd in Feb2012, heeft een ambtstermijn van 12.67 jaar. De totale jaarlijkse vergoeding van { bedraagt € 2.44M, bestaande uit 21.5% salaris en 78.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.86% van de aandelen van het bedrijf, ter waarde $ 1.28M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 4.8 jaar en 6.1 jaar.
Belangrijke informatie
Daniel de Boer
Algemeen directeur
€2.4m
Totale compensatie
| Percentage CEO-salaris | 21.5% |
| Dienstverband CEO | 12.7yrs |
| Eigendom CEO | 0.9% |
| Management gemiddelde ambtstermijn | 4.8yrs |
| Gemiddelde ambtstermijn bestuur | 6.1yrs |
Recente managementupdates
Recent updates
ProQR Therapeutics N.V. (NASDAQ:PRQR) Investors Are Less Pessimistic Than Expected
Jul 15
Broker Revenue Forecasts For ProQR Therapeutics N.V. (NASDAQ:PRQR) Are Surging Higher
May 29Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?
Apr 03Health Check: How Prudently Does ProQR Therapeutics (NASDAQ:PRQR) Use Debt?
Nov 28Is ProQR Therapeutics (NASDAQ:PRQR) Using Too Much Debt?
Jul 30Despite Lacking Profits ProQR Therapeutics (NASDAQ:PRQR) Seems To Be On Top Of Its Debt
Mar 17ProQR says EU regulator seeks additional trial for lead candidate
Aug 11Here's Why ProQR Therapeutics (NASDAQ:PRQR) Can Manage Its Debt Despite Losing Money
Nov 10Investment Case On ProQR Therapeutics Gets More Enticing
Oct 01ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?
Aug 04ProQR Therapeutics: Looks Interesting Ahead Of Next Year's Pivotal Data
Jun 20It's Unlikely That ProQR Therapeutics N.V.'s (NASDAQ:PRQR) CEO Will See A Huge Pay Rise This Year
May 13ProQR Therapeutics offers a de-risked opportunity: Stifel
May 03If You Had Bought ProQR Therapeutics' (NASDAQ:PRQR) Shares A Year Ago You Would Be Down 42%
Mar 08Could The ProQR Therapeutics N.V. (NASDAQ:PRQR) Ownership Structure Tell Us Something Useful?
Feb 01
ProQR concludes enrollment in mid-stage cell therapy trial in a rare eye disorder
Jan 07ProQR Therapeutics (NASDAQ:PRQR) Has Debt But No Earnings; Should You Worry?
Dec 28A Look At ProQR Therapeutics' (NASDAQ:PRQR) Share Price Returns
Dec 01ProQR reports Q3 results
Nov 16Analyse CEO-vergoeding
| Datum | Totale vergoeding | Salaris | Bedrijfswinsten |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -€22m |
| Mar 31 2024 | n/a | n/a | -€27m |
| Dec 31 2023 | €2m | €524k | -€28m |
| Sep 30 2023 | n/a | n/a | -€37m |
| Jun 30 2023 | n/a | n/a | -€54m |
| Mar 31 2023 | n/a | n/a | -€59m |
| Dec 31 2022 | €2m | €504k | -€64m |
| Sep 30 2022 | n/a | n/a | -€69m |
| Jun 30 2022 | n/a | n/a | -€61m |
| Mar 31 2022 | n/a | n/a | -€63m |
| Dec 31 2021 | €2m | €449k | -€61m |
| Sep 30 2021 | n/a | n/a | -€57m |
| Jun 30 2021 | n/a | n/a | -€55m |
| Mar 31 2021 | n/a | n/a | -€43m |
| Dec 31 2020 | €3m | €449k | -€47m |
| Sep 30 2020 | n/a | n/a | -€52m |
| Jun 30 2020 | n/a | n/a | -€51m |
| Mar 31 2020 | n/a | n/a | -€58m |
| Dec 31 2019 | €2m | €449k | -€56m |
| Sep 30 2019 | n/a | n/a | -€51m |
| Jun 30 2019 | n/a | n/a | -€45m |
| Mar 31 2019 | n/a | n/a | -€40m |
| Dec 31 2018 | €1m | €445k | -€37m |
| Sep 30 2018 | n/a | n/a | -€35m |
| Jun 30 2018 | n/a | n/a | -€40m |
| Mar 31 2018 | n/a | n/a | -€44m |
| Dec 31 2017 | €1m | €353k | -€44m |
Compensatie versus markt: De totale vergoeding ($USD 2.70M ) Daniel } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 677.23K ).
Compensatie versus inkomsten: De vergoeding van Daniel is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.
CEO
Daniel de Boer (41 yo)
12.7yrs
Tenure
€2,439,000
Compensatie
Mr. Daniel Anton de Boer has been the Chief Executive Officer and Member of Management Board at ProQR Therapeutics N.V. since February 21, 2012. He serves as Member of Strategic Advisory Board at Hybridize...
Leiderschapsteam
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder | 12.7yrs | €2.44m | 0.86% € 1.2m | |
| Founder & Independent Member of Supervisory Board | no data | €150.00k | 0.52% € 740.5k | |
| Chief Corporate Development Officer | 2.3yrs | €1.31m | 0.56% € 809.6k | |
| Co-Founder | 12.7yrs | €34.00k | geen gegevens | |
| Chief Financial Officer | 1.9yrs | geen gegevens | geen gegevens | |
| Chief People & Operations Officer | 4.8yrs | geen gegevens | geen gegevens | |
| Vice President of Investor Relations & Corporate Communications | no data | geen gegevens | geen gegevens | |
| Junior Financial Controller | no data | geen gegevens | geen gegevens |
4.8yrs
Gemiddelde duur
54yo
Gemiddelde leeftijd
Ervaren management: Het managementteam van PRQR wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.8 jaar).
Bestuursleden
| Naam | Positie | Tenure | Compensatie | Eigendom |
|---|---|---|---|---|
| Founder & Independent Member of Supervisory Board | 10.8yrs | €150.00k | 0.52% € 740.5k | |
| Independent Member of Supervisory Board | 10.1yrs | €126.00k | 0% € 0 | |
| Member of Scientific Advisory Board | 7.3yrs | geen gegevens | geen gegevens | |
| Supervisory Board Member | 1.4yrs | €271.00k | 0.032% € 46.6k | |
| Chairman of the Board of Directors & Chairman of Scientific Advisory Board | 4.3yrs | €132.00k | 0.075% € 108.3k | |
| Member of the Board of Directors | 5.8yrs | €127.00k | 0% € 0 | |
| Supervisory Board Member & Member of Scientific Advisory Board | 4.3yrs | geen gegevens | geen gegevens | |
| Member Scientific Advisory Board | 6.5yrs | geen gegevens | geen gegevens | |
| Member of Scientific Advisory Board | 6.4yrs | geen gegevens | geen gegevens | |
| Member of the Board of Directors | 1.8yrs | €84.00k | 0% € 0 |
6.1yrs
Gemiddelde duur
63.5yo
Gemiddelde leeftijd
Ervaren bestuur: De raad van bestuur van PRQR wordt beschouwd als ervaren (gemiddelde ambtstermijn 6.1 jaar).